# Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC

> **NCT01062503** · — · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 48 (actual)

## Conditions studied

- Metastatic Prostate Cancer
- Bone Metastasis

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT01062503
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2015-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01062503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01062503, "Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01062503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*